



## Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

August 6, 2024

NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- [Acumen Pharmaceuticals, Inc.](#) (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this [link](#). After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The webcast audio will be available via this [link](#).

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at [www.acumenpharm.com](http://www.acumenpharm.com).

### **About Acumen Pharmaceuticals, Inc.**

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A $\beta$ Os) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on A $\beta$ Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A $\beta$ Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit [www.acumenpharm.com](http://www.acumenpharm.com).

### **Investors:**

Alex Braun

[abraun@acumenpharm.com](mailto:abraun@acumenpharm.com)

### **Media:**

[AcumenPR@westwicke.com](mailto:AcumenPR@westwicke.com)